Novo Nordisk (NYSE: NVO) faced challenges in 2025, including competition and slowing growth for top drugs like Ozempic and Wegovy. However, 2026 looks promising with label expansions for Wegovy, leading to potential sales exceeding $1 billion for metabolic dysfunction-associated steatohepatitis (MASH).

Novo Nordisk’s ongoing success with Wegovy is expected to boost its sales and overall growth. The company’s larger size and budget compared to competitors position it well in the underserved MASH market. 2026 may see improvements in top-line growth due to recent drug approvals and expansions.

Looking ahead, Novo Nordisk aims to regain ground in the GLP-1 market, focusing on pipeline candidates like amycretin and UBT251. These promising products mimic gut hormones and could drive the company’s stock value with positive interim data expected next year.

Despite setbacks in 2025, Novo Nordisk is poised for a turnaround, with potential launches like CagriSema and strong sales from Wegovy and Ozempic. The company’s stock remains reasonably valued, making it a potential buy for investors looking for growth opportunities in the healthcare sector.

Read more at Yahoo Finance: 2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026